THE NHS is failing to keep up with science, experts blasted after breakthrough new dementia drugs were rejected again by the ...

Two drugs – donanemab and lecanemab – have been rejected for NHS use because their benefits are "too small" to justify their ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to ...

The decision to block Alzheimer’s ‘wonder’ drugs for use by NHS patients will be appealed against. The two breakthrough drugs ...

June is brain and Alzheimer’s Disease Awareness Month, a time to focus on our brains’ health. As we age, memory lapses and ...

Playwright Molly McFadden, who carries the Alzheimer's gene, will present her one-woman show featuring a puppet named Memory ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...

Contrary to popular belief, a new study suggests that people with a higher genetic risk for Alzheimer’s may become more socially engaged—not less.

Margaret (name changed) had lived in rural Kentucky her entire 78-year life when the words started disappearing. Simple ones ...

According to the Cleveland Clinic, early symptoms of dementia can include short-term memory loss, behavioral changes, and ...

With tremendous social and economic costs, dementia is now the seventh leading cause of death globally, affecting 57 million ...